Edgestream Partners’s Sage Therapeutics SAGE Stock Holding History

Edgestream Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-27,349	Closed	-$1.29M	–	951
2023 Q2	$1.29M	Buy	+27,349	New	+$1.36M	0.12%	303

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edgestream Partners's SAGE Position: Q3 2023 in Review

Edgestream Partners sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 27,349 shares — an estimated $1.29M sold.

Edgestream Partners first reported a position in SAGE in Q2 2023 and held it in 1 quarter. The position peaked at $1.29M in Q2 2023. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

Edgestream Partners reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
Edgestream Partners sold 27,349 Sage Therapeutics shares in Q3 2023, an estimated $1.29M.
Edgestream Partners first reported a position in Sage Therapeutics in Q2 2023 and held it in 1 quarter.
Edgestream Partners's Sage Therapeutics position peaked at $1.29M in Q2 2023.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Edgestream Partners's 13F filing for Q3 2023, filed 15 Nov 2023.